- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05326750
Nicht-invasive Neurostimulation als Werkzeug für Diagnostik und Management von neurodegenerativen Erkrankungen
Double blinded, sham-controlled, randomized trial on repeated transcranial alternating current brain stimulation (tACS) in neurodegenerative diseases. The investigators will evaluate whether a 4-times daily repeated stimulation with gamma tACS on the posterior parietal cortex can improve symptoms in patients with neurodegenerative diseases, including dementia with Lewy Bodies, Alzheimer's disease, idiopathic normal pressure hydrocephalus and Frontotemporal dementia.
Studienübersicht
Status
Intervention / Behandlung
Detaillierte Beschreibung
Double blinded, sham-controlled, randomized trial on repeated transcranial alternating current brain stimulation (tACS) in neurodegenerative diseases. The investigators will evaluate whether a 4-times daily repeated stimulation with gamma tACS on the posterior parietal cortex can improve symptoms in patients with neurodegenerative diseases, including dementia with Lewy Bodies, Alzheimer's disease, idiopathic normal pressure hydrocephalus and Frontotemporal dementia.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Eino Solje, MD, PhD
- Telefonnummer: +358 17 713 311
- E-Mail: eino.solje@uef.fi
Studienorte
-
-
-
Kuopio, Finnland
- Rekrutierung
- Kuopio University Hospital
-
Kontakt:
- Eino Solje
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Mild Cognitive Impairment due to Alzheimer's disease
- Dementia with Lewy Bodies
- Frontotemporal dementia
- Idiopathic normal pressure hydrocephalus (iNPH)
Exclusion Criteria:
- History of seizures
- Pregnancy
- Metal implants in the head (except dental fillings)
- Electronic implants (i.e. pace-maker, implanted medical pump)
- Age <18 years
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Real tACS
Four sessions (once a day, during four consecutive days) of gamma tACS (40 Hz) at 3 mA over the superior parietal cortex (Precuneus) |
Single session of gamma tACS (40 Hz) over the superior parietal cortex |
|
Placebo-Komparator: Sham tACS
Four sessions of sham tACS (once a day, during four consecutive days) over the superior parietal cortex (Precuneus) |
Single session of gamma tACS (40 Hz) over the superior parietal cortex |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Changes in Rey Auditory Verbal Learning Test score
Zeitfenster: Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention
|
Participants are given a list of 15 unrelated words repeated over five different trials and are asked to repeat. Another list of 15 unrelated words are given and the patient must again repeat the original list of 15 words and then again after 30 minutes. The examiner reads aloud 15 unrelated words and the participant is asked to recall the words after each of the five trials. After a 15 minute delay, the participant is asked again to recall the words. The score ranges from 0 (worst performance) to 75 (best performance). |
Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention
|
|
Changes in Rey Auditory Verbal Learning Test, recognition
Zeitfenster: Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention
|
Participants are given a list of 15 unrelated words repeated over five different trials and are asked to repeat. After a 15 minute delay, the participant is asked to recognise the original 15 words intermixed with 31 distractor words. The score of the recognition part ranges from 0 (worst performance) to 46 (best performance). |
Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention
|
|
Changes in orientation to time and place (MMSE questions 1-10)
Zeitfenster: Baseline (immediately before the intervention), immediately after the last intervention, 4 weeks after the last intervention
|
10 questions about the orientation. The score ranges from 0 (worse performance) to 10 (best performance). |
Baseline (immediately before the intervention), immediately after the last intervention, 4 weeks after the last intervention
|
|
Changes in Trail Making A & B tests
Zeitfenster: Baseline (immediately before the intervention), immediately after the 4th intervention, 4 weeks after the last intervention
|
TMT A & B tests. Time to perform set is recorded. |
Baseline (immediately before the intervention), immediately after the 4th intervention, 4 weeks after the last intervention
|
|
Changes in INECO Frontal Screening test
Zeitfenster: Baseline (immediately before the intervention), immediately after the 4th intervention, 4 weeks after the last intervention
|
Test battery assessing frontal lobe functions. The score ranges from 0 (worse performance) to 30 (best performance) |
Baseline (immediately before the intervention), immediately after the 4th intervention, 4 weeks after the last intervention
|
|
Changes in phonemic fluency
Zeitfenster: Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention
|
Person is requested to provide as many words as possible starting with certain letter. The score is the sum of all acceptable words produced in one minute. |
Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in SAI measurements
Zeitfenster: Baseline (immediately before the intervention), immediately after the last intervention
|
By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of gamma tACS on short latency afferent inhibition (SAI), which is a marker of cholinergic neurotransmission. |
Baseline (immediately before the intervention), immediately after the last intervention
|
|
Change in SICI measurements
Zeitfenster: Baseline (immediately before the intervention), immediately after the last intervention
|
By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of gamma tACS on short interval intracortical inhibition (SICI), which is a marker of gabaergic neurotransmission. |
Baseline (immediately before the intervention), immediately after the last intervention
|
|
Change in ICF measurements
Zeitfenster: Baseline (immediately before the intervention), immediately after the last intervention
|
By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of gamma tACS on intracortical facilitation (ICF), which is a marker of glutamatergic neurotransmission. |
Baseline (immediately before the intervention), immediately after the last intervention
|
|
Change in modified Frontal Behavioral Inventory (FBI-mod) score
Zeitfenster: Baseline (immediately before the intervention), immediately after the last intervention, 4 weeks after the last intervention
|
The modified Frontal Behavioral Inventory (FBI-mod) is used to assess behavioral symptoms associated with frontotemporal dysfunction. The questionnaire evaluates changes in behavioral and personality features. Higher scores indicate a greater severity of behavioral symptoms. |
Baseline (immediately before the intervention), immediately after the last intervention, 4 weeks after the last intervention
|
|
Change in Neuropsychiatric Inventory (NPI) score
Zeitfenster: Baseline (immediately before the intervention), immediately after the last intervention, 4 weeks after the last intervention
|
The Neuropsychiatric Inventory (NPI) is used to assess neuropsychiatric symptoms, including their frequency and severity. Higher total scores indicate a greater burden of neuropsychiatric symptoms. |
Baseline (immediately before the intervention), immediately after the last intervention, 4 weeks after the last intervention
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Eino Solje, MD, PhD, Kuopio University Hospital
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Synucleinopathien
- Erkrankungen des Gehirns
- Erkrankungen des zentralen Nervensystems
- Erkrankungen des Nervensystems
- Psychische Störungen
- Stoffwechselerkrankungen
- Neurokognitive Störungen
- Demenz
- Tauopathien
- Neurodegenerative Krankheiten
- Bewegungsstörungen
- Parkinsonsche Störungen
- Erkrankungen der Basalganglien
- TDP-43 Proteinopathien
- Proteostase-Mängel
- Frontotemporale Lobärdegeneration
- Ernährungs- und Stoffwechselerkrankungen
- Alzheimer Erkrankung
- Frontotemporale Demenz
- Lewy-Körper-Krankheit
Andere Studien-ID-Nummern
- KUH5772859
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Pseudonymized data upon request, according to Finnish national and EU GDPR regulations
IPD-Sharing-Zeitrahmen
Data will be shared after the study completion indefinitely.
IPD-Sharing-Zugriffskriterien
Reasonable request
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .